Stay updated with breaking news from Multi Characteristic Opsin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today...
/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today...
Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.
/PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced...
In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.